Tags

Type your tag names separated by a space and hit enter

Clinical features and treatment of COVID-19 patients in northeast Chongqing.
J Med Virol. 2020 Jul; 92(7):797-806.JM

Abstract

The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19.

Links

PMC Free PDF

Authors+Show Affiliations

Wan S
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China.
Xiang Y
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China. Liver Center, Yu'an Branch of Chongqing Three Gorges Central Hospital, Chongqing, China.
Fang W
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China.
Zheng Y
Pharmacy College, Chengdu University of Traditional Chinese Medicine, Key Laboratory of Standardization of Chinese Herbal Medicine, Ministry of Education, Key Laboratory of Systematic Research, Development and Utilization of Chinese Medicine Resources in Sichuan Province, Key Laboratory Breeding Base of Co-founded by Sichuan Province and Ministry of Science and Technology, Chongqing University Three Gorges Hospital, Chengdu, China.
Li B
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China.
Hu Y
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China.
Lang C
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China. Office of Research Affairs, Chongqing Three Gorges Central Hospital, Chongqing, China.
Huang D
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China.
Sun Q
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China.
Xiong Y
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China. Department of Chinese Internal Medicine, Chongqing Three Gorges Central Hospital, Chongqing, China.
Huang X
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China. Critical Care Medicine, Chongqing Three Gorges Central Hospital, Chongqing, China.
Lv J
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China. Department of Hematology, Chongqing Three Gorges Central Hospital, Chongqing, China.
Luo Y
Department of Mathematics, College of Medical Information, Chongqing Medical University, Chongqing, China.
Shen L
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China.
Yang H
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China.
Huang G
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China.
Yang R
Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing University Three Gorges Hospital, Chongqing, China.

MeSH

AdolescentAdrenal Cortex HormonesAdultAgedAnti-Bacterial AgentsAntiviral AgentsBetacoronavirusBiomarkersCOVID-19COVID-19 TestingCardiovascular DiseasesChinaClinical Laboratory TechniquesCoronavirus InfectionsCoughDiabetes ComplicationsDiabetes MellitusDrug CombinationsDrugs, Chinese HerbalFatigueFemaleFeverHumansInterferonsLopinavirMaleMiddle AgedNeoplasmsPandemicsPneumonia, ViralRetrospective StudiesRitonavirSARS-CoV-2Severity of Illness IndexTomography, X-Ray Computed

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32198776

Clinical Trial Links

Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)

Citation

Wan, Suxin, et al. "Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing." Journal of Medical Virology, vol. 92, no. 7, 2020, pp. 797-806.
Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797-806.
Wan, S., Xiang, Y., Fang, W., Zheng, Y., Li, B., Hu, Y., Lang, C., Huang, D., Sun, Q., Xiong, Y., Huang, X., Lv, J., Luo, Y., Shen, L., Yang, H., Huang, G., & Yang, R. (2020). Clinical features and treatment of COVID-19 patients in northeast Chongqing. Journal of Medical Virology, 92(7), 797-806. https://doi.org/10.1002/jmv.25783
Wan S, et al. Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. J Med Virol. 2020;92(7):797-806. PubMed PMID: 32198776.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical features and treatment of COVID-19 patients in northeast Chongqing. AU - Wan,Suxin, AU - Xiang,Yi, AU - Fang,Wei, AU - Zheng,Yu, AU - Li,Boqun, AU - Hu,Yanjun, AU - Lang,Chunhui, AU - Huang,Daoqiu, AU - Sun,Qiuyan, AU - Xiong,Yan, AU - Huang,Xia, AU - Lv,Jinglong, AU - Luo,Yaling, AU - Shen,Li, AU - Yang,Haoran, AU - Huang,Gu, AU - Yang,Ruishan, Y1 - 2020/04/01/ PY - 2020/3/6/received PY - 2020/3/17/revised PY - 2020/3/18/accepted PY - 2020/3/22/pubmed PY - 2020/6/25/medline PY - 2020/3/22/entrez KW - COVID-19 KW - clinical features KW - cognition KW - northeast Chongqing KW - treatment SP - 797 EP - 806 JF - Journal of medical virology JO - J Med Virol VL - 92 IS - 7 N2 - The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/32198776/Clinical_features_and_treatment_of_COVID_19_patients_in_northeast_Chongqing_ DB - PRIME DP - Unbound Medicine ER -